Heart failure (HF) impacts nearly 6.5 million Americans over the age of 20 in the US, with approximately 960,000 new cases each year. And HF readmission rates have worsened over the past decade. Optimizing acute inpatient decongestion is critical in mitigating HF morbidity and mortality, but few new treatment strategies have emerged in recent years.
With the most accurate source of RWD for HF being the nearly 20 year old ADHERE registry, Reprieve Cardiovascular needed immediate access to a contemporary, nationally representative real-world dataset with complete, patient-level data and rich clinical detail and came to Truveta.
Download this case study to see how they:
- Identified a patient population 3x the size of the ADHERE registry
- Validated the need for a new HF decongestion device
- Optimized clinical trial design, enabling prediction of enrollment and outcomes
